PTAB

Vicor patents asserted against infringing NBMs withstand validity challenges

Retrieved on: 
星期二, 五月 28, 2024
Inter partes review, IPR, Patent, Delta Electronics, PTAB, NBM, IP, ITC, Foxconn, Attention, TPU, Artificial intelligence, District court, VICR, GPU

On July 13, 2023, Vicor filed a complaint at the ITC against Delta alleging infringement of three Vicor patents: U.S. Patent Nos.

Key Points: 
  • On July 13, 2023, Vicor filed a complaint at the ITC against Delta alleging infringement of three Vicor patents: U.S. Patent Nos.
  • 9,166,481 (the “‘481 patent”); 9,516,761 (the “‘761 patent”) and 10,199,950 (the “’950 patent”) (“the asserted patents”).
  • Copycat Non-isolated Bus Converter Modules (“NBMs”), manufactured by infringing competitors, practice the asserted patents.
  • Chief Executive Officer, Dr. Patrizio Vinciarelli, stated: “PTAB decisions, denying all of Delta’s IPRs, debunk expert opinions proffered in Delta’s ill-conceived, failed attempts to invalidate Vicor patents.

One-Year Results of the DETOUR2 Trial published in the Journal of Vascular Surgery (JVS)

Retrieved on: 
星期一, 五月 13, 2024
Health, Medical Devices, Surgery, General Health, Clinical Trials, Research, Science, Thrombosis, Patient, Embolism, DVT, PTAB, MD, Incidence, Journal, Freedom, Vascular disease, Multimedia, SFA

Endologix LLC , a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, has announced the online publication of the one-year results of the DETOUR2 Trial in the Journal of Vascular Surgery ( JVS1 ).

Key Points: 
  • Endologix LLC , a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, has announced the online publication of the one-year results of the DETOUR2 Trial in the Journal of Vascular Surgery ( JVS1 ).
  • Percutaneous Transmural Arterial Bypass (PTAB) with the DETOUR System offers a novel approach to bypass the SFA using the vein as a conduit.
  • The study highlighted low rates of complications, deep venous thrombosis (DVT), and clinically-driven target lesion revascularization (CD-TLR), and excellent one-year primary patency.
  • DETOUR2 trial outcomes demonstrate clinical utility of percutaneous transmural bypass for the treatment of long segment, complex femoropopliteal disease.

Vizgen Issued a New US Patent for Its MERFISH Technology

Retrieved on: 
星期二, 四月 16, 2024
Research, Patent Law, Genetics, Health Technology, Professional Services, Biotechnology, Health, Other Science, Science, United States patent law, RNA, Harvard College, Patent, Chemistry, PTAB, AACR, Harvard University, Inter partes review

Vizgen has secured key patents protecting its innovative pioneering technology in the United States and abroad, adding to its growing patent portfolio as Vizgen continues to invest in the development of its groundbreaking technologies.

Key Points: 
  • Vizgen has secured key patents protecting its innovative pioneering technology in the United States and abroad, adding to its growing patent portfolio as Vizgen continues to invest in the development of its groundbreaking technologies.
  • This newly allowed patent is owned by The President and Fellows of Harvard College and is exclusively licensed to Vizgen.
  • To date, there are over two hundred peer-reviewed and preprint publications on MERFISH technology and thousands of samples have been processed on MERSCOPE instruments.
  • During AACR 2024, Vizgen unveiled the MERSCOPE® Ultra Platform and shared new MERFISH 2.0 chemistry data.

Buchanan's Expanding Delaware Office Adds Former Deputy Chief Judge of the PTAB to Its IP Roster

Retrieved on: 
星期五, 四月 26, 2024
Johns Hopkins University, IP, System, Intellectual property, Heart, Private practice, Nobel Prize, Vice, Culture, Senior, Patent, Leahy–Smith America Invents Act, PTAB, Lawyer, AIA

WILMINGTON, Del., April 26, 2024 /PRNewswire/ -- Buchanan Ingersoll & Rooney is pleased to announce that it has added former Patent Trial and Appeal Board (PTAB) Deputy Chief Judge James T. Moore to its expanding Delaware office.

Key Points: 
  • WILMINGTON, Del., April 26, 2024 /PRNewswire/ -- Buchanan Ingersoll & Rooney is pleased to announce that it has added former Patent Trial and Appeal Board (PTAB) Deputy Chief Judge James T. Moore to its expanding Delaware office.
  • He joins the firm's Intellectual Property (IP) section and Patent Office Litigation practice group.
  • He has judicial experience in all areas of PTAB jurisdiction, including appeals, interferences, America Invents Act (AIA) trials, and management as a member of the Senior Executive Service as Vice Chief Judge, Deputy Chief Judge, and Acting Chief Judge of the PTAB.
  • "We are pleased to welcome Judge Moore to our IP group and our growing Delaware office," said Joseph Dougherty, the firm's Chairman and CEO.

RPX Corporation Launches RPX Empower

Retrieved on: 
星期二, 四月 23, 2024
Intelligence, News, NPES, Patent, PTAB, RPX, Research, Acquisition, ITC, Empower

"RPX Empower is a patent intelligence platform that I believe will significantly enhance both the capabilities of our existing patent-related tools and the model through which they are delivered," said Dan McCurdy, Chief Executive Officer of RPX.

Key Points: 
  • "RPX Empower is a patent intelligence platform that I believe will significantly enhance both the capabilities of our existing patent-related tools and the model through which they are delivered," said Dan McCurdy, Chief Executive Officer of RPX.
  • RPX Empower includes the ability to search and apply advanced analytics to detailed information on patent litigation, patent portfolio analysis, SEPs, NPEs, and much more.
  • Empower is backed by RPX's 15+ years of patent analysis and transaction experience.
  • To learn more about RPX Empower, visit empower.rpxcorp.com .

RPX Corporation Launches RPX Empower

Retrieved on: 
星期二, 四月 23, 2024
Intelligence, News, NPES, Patent, PTAB, RPX, Research, Acquisition, ITC, Empower

"RPX Empower is a patent intelligence platform that I believe will significantly enhance both the capabilities of our existing patent-related tools and the model through which they are delivered," said Dan McCurdy, Chief Executive Officer of RPX.

Key Points: 
  • "RPX Empower is a patent intelligence platform that I believe will significantly enhance both the capabilities of our existing patent-related tools and the model through which they are delivered," said Dan McCurdy, Chief Executive Officer of RPX.
  • RPX Empower includes the ability to search and apply advanced analytics to detailed information on patent litigation, patent portfolio analysis, SEPs, NPEs, and much more.
  • Empower is backed by RPX's 15+ years of patent analysis and transaction experience.
  • To learn more about RPX Empower, visit empower.rpxcorp.com .

Increased Adoption of Artificial Intelligence Across the Healthcare Industry Driving Strong Market Growth

Retrieved on: 
星期三, 三月 27, 2024
PWD, African Americans, Conditional sentence, Patient, Big data, Intellectual property, Lidar, Artificial intelligence, Certification, AMD, Risk, Sony, PALM, 3D, NIH, Treatment, Culture, Safety, OTCQB, CE marking, Weather, SSS, Prevalence, Radiology, Intelligence, Family, PLTR, Depth perception, Triage, News, Historical trauma, Cancer, AI, MDR, MPH, Butterfly, Health equity, Diagnosis, Arrhythmia, Health, Butterfly network, Growth, Patent, Perception, SNM, PTAB, AIP, FAAFP, FRCS, Medical device

In diagnostics, AI enables healthcare providers to make the most appropriate treatment decisions for their patients.

Key Points: 
  • In diagnostics, AI enables healthcare providers to make the most appropriate treatment decisions for their patients.
  • Mordor Intelligence continued: “The increased prevalence of cancer and the high burden of other chronic diseases are, in turn, increasing the demand for accurate diagnosis and treatment.
  • This is likely to increase the adoption of AI for early diagnosis purposes, ultimately boosting the market growth.
  • The use of artificial intelligence in the North American healthcare market is being driven by the increasing use of advanced technology in healthcare systems, the growth in funding of AI-based startups, the rising burden of chronic diseases in the country, the growing need to reduce healthcare costs, and the implementation of big data in healthcare.

Alzheon Announces that United States Federal Circuit Affirmed Decision of U.S. Patent Office Invalidating Risen (Suzhou) Pharmaceutical Technology Co., Ltd.’s Patent on Isotopically Enriched Forms of ALZ-801/Valiltramiprosate

Retrieved on: 
星期一, 四月 8, 2024
Biotechnology, Professional Services, Health, Patent Law, Pharmaceutical, Neurology, Research, Genetics, Legal, Science, Clinical Trials, Comment, Patent, Patient, NDA, PTAB, Federal Circuit Court, Doctor of Philosophy, IPR, Prodrug, Rule 34, Pharmaceutical industry

The decision was affirmed without discussion by the Federal Circuit Court (Case No.

Key Points: 
  • The decision was affirmed without discussion by the Federal Circuit Court (Case No.
  • In 2020, Alzheon petitioned the Patent Trial and Appeal Board (PTAB) of the U.S. Patent Office (USPTO) to institute an Inter-Parties Review (IPR) of Risen’s U.S. Patent No.
  • Risen appealed the PTAB’s decision to the United States Court of Appeals for the Federal Circuit.
  • “Alzheon is pleased that the U.S. Federal Circuit affirmed the Patent Trial and Appeal Board’s decision to invalidate all claims of Risen’s patent.

Novarad Wins Patent Litigation with Medivis Over Augmented Reality Navigation System

Retrieved on: 
星期三, 三月 20, 2024
Anatomy, VISAR, 3D, PTAB, Surgeon, Patent, Data, FDA, Physician, Medicine

Salt Lake City, Utah, March 20, 2024 (GLOBE NEWSWIRE) -- Novarad Corporation, a leading provider of augmented reality surgical navigation, is thrilled to announce a significant legal victory in a recent patent case.

Key Points: 
  • Salt Lake City, Utah, March 20, 2024 (GLOBE NEWSWIRE) -- Novarad Corporation, a leading provider of augmented reality surgical navigation, is thrilled to announce a significant legal victory in a recent patent case.
  • The decision, reached in Novarad Corp. v. Medivis, Inc., is poised to have far-reaching consequences for Novarad and its groundbreaking augmented reality product, VisAR.
  • In the case of Novarad Corp. v. Medivis, Inc., the Patent Trial and Appeal Board (PTAB) rendered a decision in favor of Novarad; dismissing a petition to invalidate Novarad’s patent.
  • "With this legal victory behind us, we are more determined than ever to continue advancing the frontiers of augmented reality technology in medicine."

Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
星期三, 三月 13, 2024
Research, PRINT, SVB, Patient, Pulmonary hypertension, Sale, NDA, PTAB, Orthostatic hypertension, Promotion, Safety, Security, PAH, FDA, Food, Cryptocurrency

ET

Key Points: 
  • ET
    MORRISVILLE, N.C., March 13, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the full year ended December 31, 2023.
  • ET to discuss the 2023 financial results and provide a corporate update.
  • In December 2023, the previous ruling by the Patent Trial and Appeal Board (PTAB) that all of the claims in U.S. Patent No.
  • The year ended December 31, 2023 included a $2.3 million loss on extinguishment of debt related to repayment of the A&R SVB LSA in January 2023.